Activity Date: 04/22/2021
Registration is not configured for this course.This course is designed for pharmacists, nurse practitioners or other health care professionals involved in the comprehensive medication management of psychiatric and/or neurological patients.
Depressive disorders are the most common comorbid psychiatric disorders among those with alcohol use disorder (AUD). Up to one third of those with depression have AUD. Illness severity is greater and the prognosis is poorer when these co-occur, compared to either disorder by itself. For those with major depressive disorder whose symptoms fail to adequately respond to treatment, patients should be evaluated for concurrent alcohol or other substance abuse. Recovery from depression and comorbid AUD appears to be linked, with the remission from one condition strongly related to remission from the other. Antidepressants are effective for the treatment of depression in patients with AUD, with a number needed to treat of 9, and the severity of drinking does not impact antidepressant effectiveness. Further, combining antidepressants and alcohol use disorder medications for this population in clinical trials has demonstrated benefit, with positive outcomes for both AUD and depressive symptoms. There are no significant drug interactions between antidepressants and naltrexone, acamprosate, or topiramate, medications used to manage AUD. Despite this, psychiatric providers are often uncomfortable addressing comorbid alcohol use. In this session, participants gain knowledge in treating comorbid depression and AUD.
To receive ACPE credit for the live session at the Annual Meeting, you must:
Upon successful completion, ACPE credit is reported within 24 hours to CPE Monitor although transcripts can be retrieved by participants online in their ACPE Transcript.
AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:
AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 8.1 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Dana Chiulli, PharmD, BCPP
View biographical information
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
2021 Program Committee
|
Shari N. Allen, PharmD, BCPP Assistant Professor PCOM-SOP Suwanee, GA No Relevant Financial Relationships to Disclose |
 Jolene R. Bostwick, PharmD, BCPP, BCPS
Program Administrative Chair
Assistant Dean for Co-Curriculum and Professional Development & Clinical ProfessorUniversity of Michigan College of Pharmacy Ann Arbor, MI No Relevant Financial Relationships to Disclose |
Bridget Bradley, PharmD, BCPP |
|
Lauren M. Brown, PharmD, BCPP Clinical Pharmacy Specialist, Psychiatry South Texas Veterans Health Care System San Antonio, TX No Relevant Financial Relationships to Disclose |
Austin R. Campbell, PharmD, BCPP |
|
Chelsea N. Carr, PharmD, BCPP Advanced Practice Pharmacist - Psychiatry University of Maryland - Spring Grove Hospital Center Catonsville, MD No Relevant Financial Relationships to Disclose |
|
Jordan Cooler, PharmD, BCPP Clinical Assistant Professor University of South Carolina College of Pharmacy Columbia, SC No Relevant Financial Relationships to Disclose |
|
Amber R. Douglass, PharmD, BCPS, BCPP Clinical Pharmacy Specialist - Mental Health VA Tennessee Valley Healthcare System Murfreesboro, TN No Relevant Financial Relationships to Disclose |
 Kristen N. Gardner, PharmD, BCPP
Program Committee Chair
Clinical Pharmacy Specialist - Behavioral HealthKaiser Permanente Colorado Denver, CO External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Biostrategies - one time consultant re:LAIAs |
|
Robert J. Haight, PharmD, BCPP Clinical Pharmacist | Forensic Services Saint Peter Regional Treatment Center (SPRTC), Minnesota Department of Human Services Saint Peter, MN No Relevant Financial Relationships to Disclose |
|
Suzanne C. Harris, PharmD, BCPP Clinical Assistant Professor/UNC Hospitals Region Experiential Director/Clinical Pharmacist Practitioner UNC Eshelman School of Pharmacy Chapel Hill, NC Educational Grants, Research Grants or Contracts: North Carolina AHEC Campus Innovations Grants |
|
Kayla D. Johnson, PharmD, BCPS, BCPP Vanderbilt Psychiatric Hospital Spring Hill, TN No Relevant Financial Relationships to Disclose |
|
Erin D. Knox, PharmD, BCPP Pharmacy Education Specialist UC Irvine Health Orange, CA No Relevant Financial Relationships to Disclose |
Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP |
|
Melissa Mitchell, PharmD, BCGP, BCPP, BCPS Senior Clinical Pharmacist RUHS MC Moreno Valley , CA External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Neurocrine Speakers Bureau - Ingrezza, Janssen Speakers Bureau - Spravato |
|
Thea R. Moore, PharmD, BCPP Associate Professor University of South Florida Tampa, FL Educational Grants, Research Grants or Contracts: Agency for Health Care Administration |
|
Kristen Neumeister, PharmD, BCPP Clinical Pharmacist- Mental Health John Peter Smith Hospital Fort Worth, TX No Relevant Financial Relationships to Disclose |
|
Melissa C. Palmer, PharmD, BCPP, BCPS Clinical Assistant Professor University of Missouri-Kansas City School of Pharmacy Kansas City, MO No Relevant Financial Relationships to Disclose |
|
Lindsey Peters, PharmD, BCPS Assistant Professor of Pharmacy Practice Ohio Northern University Ada, OH No Relevant Financial Relationships to Disclose |
|
Kristina Reinstatler, PharmD, BCPP, MBA Clinical Pharmacy Specialist UC Health University of Cincinnati Medical Center Cincinnati, OH No Relevant Financial Relationships to Disclose |
|
Michael D. Shuman, PharmD, BCPP Staff Pharmacist Central State Hospital Louisville, KY No Relevant Financial Relationships to Disclose |
|
Sheryl Thedford, PharmD, PhD, BCPS, BCPP Clinical Psychiatric Pharmacist University of Maryland, Spring Grove Hospital Center Catonsville, MD No Relevant Financial Relationships to Disclose |
|
Taylor A. Thomas, PharmD, BCPP Clinical Pharmacy Specialist- Mental Health VA Northern Indiana Health Care System Fort Wayne, IN No Relevant Financial Relationships to Disclose |
All relevant relationships have been mitigated.
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: Memantine and ketamine ? off-label use/future directions
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.
